HIV

The panel discusses considerations for payers as well as patient adherence to treatment in MDR HIV.

Body mass index and nadir CD4 count were major factors in SARS-CoV-2 humoral immune repertoire among people with HIV.

Researchers found that only 8 of 18 HIV risk assessment models have been externally validated and show moderate-to-good discrimination ability for HIV infection prediction.

Therapy adjustments in MDR HIV are explored by Dr Sension.

Optimized background regimens are highlighted in the treatment approach for MDR HIV by Michael Sension, MD.

The study also showed, despite an existing association between discrimination based on sexual orientation and HIV pre-exposure prophylaxis (PrEP) use, increased resilience reduced the effects of such discrimination on PrEP use.

The 3 companies announced a partnership to provide free, same-day prescription delivery of HIV pre-exposure prophylaxis (PrEP) and antiretroviral medications.

Dr Haumschild leads a discussion highlighting goals of therapy and social determinants of health affecting MDR HIV diagnosis and treatment.

A panel of experts explore burdens impacting patients diagnosed with MDR HIV.

A global case series described a severe form of mpox linked to a 15% mortality rate among people living with HIV and low CD4 counts.

Michael Sension, MD, provides insights on resistance mechanisms promoting MDR HIV.

Ryan Haumschild, PharmD, MS, MBA, opens a panel discussion surrounding the incidence and prevalence of multidrug-resistant (MDR) HIV.

A fifth person has been cured of HIV following a stem cell transplant for cancer; a new study examining a treatment of spinal cord stimulation after stroke had favorable results; some food companies enraged by proposed FDA healthy food guidelines.

An HIV prevention and treatment program implemented in Zambian criminal justice facilities demonstrated high levels of pre-exposure prophylaxis (PrEP) uptake among at-risk individuals.

Interviews with 2241 men who have sex with men (MSM) without HIV showed high levels of HIV testing, but lower levels of preventative treatment in 2021.

Biden’s State of the Union (SOTU) address emphasized drug access for those on Medicare, the Cancer Moonshot, and more; HIV diagnoses are increasing in Washington, DC, from missed wellness visits and preventive visits upended during the start of COVID-19; California online women’s pharmacy The Pill Club will pay $18.3 million in Medicaid fraud settlement with California.

Johnson & Johnson (J&J) ends late-stage HIV vaccine trial; mothers in states with abortion bans are almost 3 times more likely to die before, during, and after birth; Sanofi hopes to release a drug for hemophilia A in 2023.

A study showed that Canadian women living with HIV were less likely to get vitamin D through dairy consumption, but more likely to take vitamin D supplements, compared with women without HIV.

This year’s most-viewed HIV content focused on disparities in HIV care, an emerging nonepidemic Kaposi sarcoma subtype, and the need for more research on hepatitis B endurance.

Of 6563 men who have sex with men (MSM) living in urban areas in 2017, only 7.7% reported HIV self-testing in the past year.

The US Preventive Services Task Force (USPSTF) announced its recommendation for HIV pre-exposure prophylaxis (PrEP).

This new study shows that family medicine physicians in rural areas tend to be less comfortable in HIV pre-exposure prophylaxis (PrEP)-related clinical activities and conversations with adolescents than those in urban areas.

Dr Halkitis is currently working on his new book "People, Politics, & Public Health: How the American People Created the HIV, COVID-19, and Other Modern-Day Pandemics," to be published by Johns Hopkins University Press.

Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope, addresses what health systems need to do to improve HIV therapy accessibility and affordability.